Alpha 2.0
Login Register
» Authors » C B Landersdorfer

C B Landersdorfer

Explore the profile of C B Landersdorfer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 70
Followers 0
Related Specialties
Pharmacology
Infectious Diseases
Top 10 Co-Authors
J B Bulitta
U Holzgrabe
M Kinzig
F Sorgel
U Stephan
G L Drusano
P N Holden
A Forrest
K R Boissonneault
B T Tsuji
Published In
Antimicrob Agents Chemother
J Vet Pharmacol Ther
Clin Microbiol Infect
Affiliations
Soon will be listed here.
Recent Articles
1.
Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii
Smith N, Lenhard J, Boissonneault K, Landersdorfer C, Bulitta J, Holden P, et al.
Clin Microbiol Infect . 2020 Feb; 26(9):1207-1213. PMID: 32061797
Objectives: Increased rates of carbapenem-resistant strains of Acinetobacter baumannii have forced clinicians to rely upon last-line agents, such as the polymyxins, or empirical, unoptimized combination therapy. Therefore, the objectives of...
2.
Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation
Black L, Landersdorfer C, Bulitta J, Griffith J, Govendir M
J Vet Pharmacol Ther . 2013 Nov; 37(3):301-11. PMID: 24219009
Clinically normal koalas (n = 6) received a single dose of intravenous enrofloxacin (10 mg/kg). Serial plasma samples were collected over 24 h, and enrofloxacin concentrations were determined via high-performance...
3.
Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers
Bulitta J, Kinzig M, Landersdorfer C, Holzgrabe U, Stephan U, Sorgel F
Antimicrob Agents Chemother . 2011 Mar; 55(6):2927-36. PMID: 21402834
Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic...
4.
Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers
Bulitta J, Landersdorfer C, Huttner S, Drusano G, Kinzig M, Holzgrabe U, et al.
Antimicrob Agents Chemother . 2010 Jan; 54(3):1275-82. PMID: 20065059
Despite the promising activity of ceftazidime against Pseudomonas aeruginosa and Burkholderia cepacia, there has not yet been a study that directly compared the pharmacokinetics (PK) of ceftazidime in cystic fibrosis...
5.
New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics
Bulitta J, Landersdorfer C, Kinzig M, Holzgrabe U, Sorgel F
Antimicrob Agents Chemother . 2009 Jun; 53(8):3462-71. PMID: 19528278
Cefuroxime axetil is widely used to treat respiratory tract infections. We are not aware of a population pharmacokinetic (PK) model for cefuroxime axetil. Our objectives were to develop a semiphysiological...